Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CFD | P00746 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | TOP1 | P11387 | 4/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2280900 | 1.00 | METTL3 (0.81) | METTL3MAPTKDM4ECFDGAA | |
| SCHEMBL13225647 | 1.00 | METTL3 (0.81) | METTL3MAPTKDM4ECFDGAA | |
| SCHEMBL30697922 | 1.00 | METTL3 (0.81) | METTL3MAPTKDM4ECFDGAA | |
| SCHEMBL4369463 | 0.93 | METTL3 (0.81) | METTL3MAPTKDM4ECFDGAA | |
| SCHEMBL4368590 | 0.93 | METTL3 (0.81) | METTL3MAPTKDM4ECFDGAA | |
| Biphenyl SCHEMBL1052588 | 0.92 | METTL3 (0.70) | METTL3MAPTKDM4ECFDGAA | |
| SCHEMBL16481909 | 0.92 | METTL3 (0.80) | METTL3MAPTKDM4ECFDGAA | |
| SCHEMBL4371718 | 0.92 | METTL3 (0.80) | METTL3MAPTKDM4ECFDGAA | |
| SCHEMBL1052589 | 0.91 | METTL3 (0.68) | METTL3MAPTKDM4ECFDGAA | |
| SCHEMBL13861860 | 0.91 | METTL3 (0.72) | METTL3MAPTCFDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091995-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2025-03-20 | — | — | US | disclosed |
| EP-4299563-A2 | COMBINATION COMPRISING A STABLE CRYSTAL OF A 4-OXOQUINOLINE COMPOUND | Japan Tobacco Inc. (JP) | 2024-01-03 | — | — | EP | disclosed |
| EP-3281939-B1 | COMBINATION COMPRISING A STABLE CRYSTAL OF A 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC (JP) | 2023-10-18 | — | — | EP | disclosed |
| US-20220235009-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2022-07-28 | — | — | US | disclosed |
| US-20190185433-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2019-06-20 | — | — | US | disclosed |
| EP-2906540-B1 | AN IMPROVED PRODUCTION METHOD AND NEW INTERMEDIATES OF SYNTHESIS OF ELVITEGRAVIR | ZENTIVA KS (CZ) | 2018-07-04 | — | — | EP | disclosed |
| EP-3281939-A1 | METHOD OF PRODUCING STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | Japan Tobacco Inc. (JP) | 2018-02-14 | — | — | EP | disclosed |
| US-20180029989-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2018-02-01 | — | — | US | disclosed |
| EP-2906529-B9 | A NEW PRODUCTION METHOD AND NEW INTERMEDIATES OF SYNTHESIS OF ELVITEGRAVIR | ZENTIVA KS (CZ) | 2017-03-15 | — | — | EP | disclosed |
| EP-2906529-B1 | A NEW PRODUCTION METHOD AND NEW INTERMEDIATES OF SYNTHESIS OF ELVITEGRAVIR | ZENTIVA KS (CZ) | 2016-11-23 | — | — | EP | disclosed |
| WO-2009035662-A1 | DEUTERATED 4 -OXOQUINOLINE DERIVATIVES FOR THE TREATMENT OF HIV INFECTION | CONCERT PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20090036684-A1 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20090036684-A1 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1992607-A1 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | Japan Tobacco, Inc. (JP) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007063869-A1 | PROCESS FOR PRODUCTION OF HIGHLY PURE QUINOLONE COMPOUND | JAPAN TOBACCO INC. (JP) | 2007-06-07 | — | — | WO | disclosed |
| US-7176220-B2 | 4-oxoquinoline compound and use thereof as pharmaceutical agent | JAPAN TOBACCO INC. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176220-B2 | 4-oxoquinoline compound and use thereof as pharmaceutical agent | JAPAN TOBACCO INC. (JP) | 2007-02-13 | — | — | US | disclosed |
| EP-1636190-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | Japan Tobacco, Inc. (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20060030710-A1 | Stable crystal of 4-oxoquinoline compound | SHIONOGI & CO., LTD. (JP) | 2006-02-09 | — | — | US | disclosed |
| WO-2005113508-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185433-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | KCNQ2, RCC1, SFPQ | METTL3 133/4885MAPT 626/4885KDM4E 248/4885 |
| US-20250091995-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | KCNQ2, KCNQ1, KCNQ5 | METTL3 107/4885MAPT 908/4885KDM4E 131/4885 |
| US-20220235009-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | GRIN2D, KCNQ2, RCC1 | METTL3 200/4885MAPT 589/4885KDM4E 269/4885 |
| US-20090036684-A1 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | IMPDH1, IMPDH2, CDK20 | METTL3 938/4885MAPT 4278/4885KDM4E 780/4885 |
| US-20060030710-A1 | Stable crystal of 4-oxoquinoline compound | KCNQ2, RCC1, SFPQ | METTL3 133/4885MAPT 626/4885KDM4E 248/4885 |
| US-20180029989-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | KCNQ2, RCC1, SFPQ | METTL3 133/4885MAPT 626/4885KDM4E 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.